+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of inhibiting HMG-CoA reductase on 7alpha-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: Contrasting findings in patients with and without prior up-regulation of the latter pathway



Effect of inhibiting HMG-CoA reductase on 7alpha-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: Contrasting findings in patients with and without prior up-regulation of the latter pathway



European Journal of Clinical Investigation 29(5): 404-412



Background: Atorvastatin is a potent inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, but its effect on bile acid synthesis is unknown. The objectives of the study were to determine the effect of atorvastatin on bile acid synthesis in patients in whom this process had not been or had been previously up-regulated by pharmacological or surgical means. Materials and methods: Four patients with heterozygous familial hypercholesterolaemia (FH) and partial ileal bypass (PIB) and 19 FH heterozygotes without PIB were treated with placebo, atorvastatin 10 mg and atorvastatin 40 mg daily, each regimen for 4 weeks. The non-PIB group was subsequently treated with bile acid (BA) sequestrant 8-16 g daily followed by co-administration of atorvastatin 10 mg, each for 4 weeks. Plasma 7alpha-hydroxy-4-cholesten-3-one (7alpha-HCO), a well-validated marker of BA synthesis was measured using high-performance liquid chromatography with UV detection. Results: The plasma 7alpha-HCO concentration was tenfold higher with placebo in the PIB than in the non-PIB group (418.5 ng mL-1 vs. 39.6 ng mL-1 P = 0.0001). Levels decreased in PIB patients treated with atorvastatin 10 mg and 40 mg daily (350.1 ng mL-1 and 174.0 ng mL-1, P = 0.007 respectively) but did not change significantly in the non-PIB group (44.7 ng mL-1 and 28.3 ng mL- respectively). Administration of BA sequestrant to non-PIB patients increased 7alpha-HCO to 197.4 ng mL-1; this decreased to 106.0 ng mL-1 during co-administration of atorvastatin 10 mg daily (P = 0.0001). Conclusion: Atorvastatin decreases the rate of BA synthesis only if the latter is up-regulated by PIB or BA sequestrants, presumably by limiting the supply of newly synthesized free cholesterol.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010526478

Download citation: RISBibTeXText

PMID: 10354197


Related references

Oat bran stimulates bile acid synthesis within 8 h as measured by 7alpha-hydroxy-4-cholesten-3-one. American Journal of Clinical Nutrition 76(5): 1111-1116, 2002

Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology 24(1): 123-126, 1996

Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. Journal of Lipid Research 44(4): 859-866, 2003

Significance of plasma 7alpha-hydroxy-4-cholesten-3-one and 27-hydroxycholesterol concentrations as markers for hepatic bile acid synthesis in cholesterol-fed rabbits. Metabolism: Clinical and Experimental 53(1): 42-48, 2003

Serum 7alpha hydroxy-4-cholesten-3-one concentrations in different types of bile acid induced diarrhoea. Gut 52(Supplement 1): A9, 2003

Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum. Digestive Diseases and Sciences 44(1): 14-19, 1999

Bile acid malabsorption as a cause of chronic diarrhea Diagnostic usefulness of 7alpha-hydroxy-4-cholesten-3-one in serum. Gastroenterology 114(4 PART 2): A414, April 15, 1998

An efficient synthesis of 7α,12α-dihydroxy-4-cholesten-3-one and its biological precursor 7α-hydroxy-4-cholesten-3-one: Key intermediates in bile acid biosynthesis. Steroids 78(9): 927-937, 2014

Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients. Steroids 73(11): 1197-1202, 2008

Comparison of simple extraction procedures in liquid chromatography-mass spectrometry based determination of serum 7α-hydroxy-4-cholesten-3-one, a surrogate marker of bile acid synthesis. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 1033-1034: 317-320, 2017

Serum 7-alpha-hydroxy-4-cholesten-3-one as a marker for bile acid loss in children. Journal of Pediatrics 163(5): 1367-71.E1, 2014

Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterology and Motility 21(7): 734-E43, 2009

Formation of bile acids in man. Metabolism of 7alpha-hydroxy-4-cholesten-3-one in normal subjects with an intact enterohepatic circulation. Biochimica et Biophysica Acta 431(2): 335-346, 1976

Simultaneous determination of plasma mevalonate and 7alpha-hydroxy-4-cholesten-3-one levels in hyperlipoproteinemia: convenient indices for estimating hepatic defects of cholesterol and bile acid syntheses and biliary cholesterol supersaturation. Hepatology 25(1): 18-26, 1997

Bile acid formation in man: metabolism of 7 -hydroxy-4-cholesten-3-one in bile fistula patients. Journal of Lipid Research 14(1): 50-53, 1973